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Abstract
Eating disorders are complex heritable conditions influenced by both genetic and environmental factors. Given the progress 
of genomic discovery in anorexia nervosa, with the identification of the first genome-wide significant locus, as well as 
animated discussion of epigenetic mechanisms in linking environmental factors with disease onset, our goal was to conduct a 
systematic review of the current body of evidence on epigenetic factors in eating disorders to inform future directions in this 
area. Following PRISMA guidelines, two independent authors conducted a search within PubMed and Web of Science and 
identified 18 journal articles and conference abstracts addressing anorexia nervosa (n = 13), bulimia nervosa (n = 6), and 
binge-eating disorder (n = 1), published between January 2003 and October 2017. We reviewed all articles and included 
a critical discussion of field-specific methodological considerations. The majority of epigenetic analyses of eating disorders 
investigated methylation at candidate genes (n = 13), focusing on anorexia and bulimia nervosa in very small samples with 
considerable sample overlap across published studies. Three studies used microarray-based technologies to examine DNA 
methylation across the genome of anorexia nervosa and binge-eating disorder patients. Overall, results were inconclusive 
and were primarily exploratory in nature. The field of epigenetics in eating disorders remains in its infancy. We encourage 
the scientific community to apply methodologically sound approaches using genome-wide designs including epigenome-
wide association studies (EWAS), to increase sample sizes, and to broaden the focus to include all eating disorder types.
Introduction
Eating disorders are serious illnesses associated with sig-
nificantly reduced health-related quality of life [1, 2]. Our
current understanding of their etiology is piecemeal and the
evidence base for their treatment, especially anorexia ner-
vosa (AN) in adults, is inadequate [3]. Over the past two
decades, family, twin, and adoption studies have robustly
shown that eating disorders reflect the pattern of complex
trait inheritance being influenced by both genetic and
environmental factors. Twin-based heritabilities for AN
range from 48 to 74%, for bulimia nervosa (BN) from 55 to
62%, and for binge-eating disorder (BED) from 39 to 45%
[4]. A genome-wide association study of AN has yielded
the first genome-wide significant locus on chromosome 12
—a chromosomal region previously associated with auto-
immune diseases including type 1 diabetes [5]. AN, fur-
thermore, shows significant genetic correlations with
various psychiatric, personality, and metabolic phenotypes,
including schizophrenia, neuroticism, glucose metabolism,
and lipid metabolism. This panel of findings has encouraged
a reconceptualization of AN as both a metabolic and psy-
chiatric disorder [6]. At the same time, epigenetic
mechanisms have garnered much interest, offering an added
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layer of gene regulatory information, which could link
external and internal environmental stimuli as well as non-
coding genetic variation with transcriptional consequences,
altering downstream phenotypes [4, 7–9]. Together with
enhanced understanding of the genetic variants underlying
heritable disease risk in eating disorders, epigenetics has the
potential to aid in disentangling the molecular genetic
pathways that contribute to the development and progres-
sion of the illnesses.
Epigenetics
In the context of this review, epigenetics refers to various
biochemical mechanisms giving rise to changes in gene
regulation, which are either heritable or characterized by
long-term stability [10]. Biologically, epigenetic mechan-
isms can be categorized into three groups: DNA modifica-
tions, histone modifications, and non-coding RNA (for
details, see Fig. 1). DNA modifications are chemical mod-
ifications that bind to the DNA itself. Histone proteins
constitute the cores around which DNA is wrapped in the
cell nucleus. They can exert an effect on gene regulation by
altering the accessibility of DNA sequences [10]. Finally,
non-coding RNAs—expressed transcripts which do not
code for proteins—have widespread effects on gene reg-
ulation via mechanisms including post-transcriptional
silencing [11, 12] or chromatin remodeling [13].
DNA methylation is the most widely studied epigenetic
mechanism in the context of complex traits thus far and
disease-associated methylomic dysregulation has been
reported for a number of psychiatric disorders, including
schizophrenia [14, 15], Alzheimer’s disease [16, 17], and
autism spectrum disorder [18, 19]. In addition to DNA
methylation, its oxidized derivatives constitute further
DNA modifications, with DNA hydroxymethylation gen-
erating increasing interest in the context of neuropsychiatric
disease, due to its enrichment in the human brain [20, 21].
While historically defined as occurring independent of the
DNA sequence, recent work has provided evidence for
widespread effects of genetic variants on epigenetic states.
In particular, methylation quantitative trait loci (mQTLs)
are increasingly being characterized: single nucleotide
polymorphisms (SNPs) that exert influence on the methy-
lation state of a CpG site, usually in close vicinity to the
SNP [22, 23].
Unlike the genome sequence, epigenetic marks are
dynamic and can vary across cell- and tissue-types, age and
development, and can be subject to environmental stimuli
including medication and stress (Fig. 2). Perhaps most
strikingly, this has been shown for tobacco smoking, which
was found to have considerable effects on DNA methyla-
tion across several genomic regions [24]. Similarly, epige-
netic profiles are highly correlated with chronological age
and an accurate predictor of age has been derived based on
the DNA methylation profiles of only around 300 CpG sites
[25]. In this sense they are more accurately characterized as
intermediate biological phenotypes and are susceptible
Fig. 1 The epigenetic profile of a human cell comprises several epi-
genetic mechanisms: a DNA methylation is the most prominent and
prevalent DNA modification characterized by an addition of a methyl-
group to cytosine in the context of cytosine-guanine dinucleotides (i.e.,
CpG sites). b Histone proteins compact chromosomal DNA in the
nucleus of the cell and regulate gene expression. Histone modifications
are chemical modifications to the N-terminal histone tails, which
extend out of the nucleosome complex. An increasing number of
modifications to amino acids in the histone tails are being identified,
including methylation, acetylation, and phosphorylation. These mod-
ifications are characterized by tissue specificity and are highly corre-
lated with different chromatin states. c Non-coding RNAs are
expressed transcripts that do not code for proteins. They can affect
gene regulation by binding to transcripts and inhibiting their transla-
tion to proteins (i.e., post-transcriptional silencing) or by guiding the
positioning of nucleosomes along the genome and thereby altering
DNA accessibility. Designed by Vinícius Gaio, London, UK
Fig. 2 Potential factors and environmental confounders influencing
epigenetic profiles. The assessment of these factors should ideally be
included in the design of a study investigating epigenetic profiles
to confounding and other problems faced in traditional
observational studies. This phenotypic feature of epigenetic
profiles means that sources of variation or confounding
need to be taken into account in the experimental design
and statistical analyses [26, 27]. For example, if all indivi-
duals in the control group are older than the affected
individuals, an epigenome-wide association study (EWAS)
may detect epigenetic differences between the two groups
related to ageing, rather than differences associated with
disease status.
Several characteristics of eating disorders support
investigation into the potential contribution of epigenetic
factors, including sex differences (i.e., females are ~8 times
more likely to suffer from AN or BN than males) [28],
periods of increased risk of onset (i.e., particularly in
adolescence and young adulthood) [29], and reported
discordance between monozygotic twins [30, 31]. Eating
disorders are associated with early life stress [32] and
emerging evidence links early life stress with epigenetic
profiles [33]. Empirical evidence confirming this association
in humans is limited due to the low availability of
brain tissue and the scarcity of large longitudinal studies
that collect information on early traumatic experiences
and biological samples enabling epigenetic analysis [34].
The largest study of early-life adversity and DNA
methylation in blood published to date identified no sig-
nificant differential methylation [35]. These characteristics
suggest that the interaction of genetic risk factors and
environmental stressors, can contribute to the onset of
eating disorders and make them an excellent target for
the examination of epigenetic effects on appetite regulation
and eating behavior.
New technical advances in genetic and epigenetic
research, including array-based genome-wide analysis
methods, have led to rapid accumulation of evidence in the
field of psychiatric epigenetics and could serve to expedite
understanding of the biology of eating disorders and to
identify more efficient treatment options [36]. Therefore,
we performed a systematic review including a critical
appraisal of the recent body of evidence of epigenetic
research in eating disorders to reflect on past research and
its limitations and offer guidance for future investigations.
Method
Search strategy
Our systematic literature review was conducted according
to PRISMA guidelines [37]. We conducted an exhaustive
literature search from 16.10.2017 until the 30.10.2017 using
the electronic databases PubMed and Web of Science
with a time limitation starting with articles published after
01.01.2003 marking the first published paper on epigenetics
of eating disorders. We used following key search terms
including (anorexia OR bulimia OR “binge-eating disorder”
OR “eating disorder”) AND (epigenetics OR methylation
OR histone OR “non-coding RNA”). The search was
repeated by the co-primary author to avoid selection bias.
Furthermore, we screened the references of published arti-
cles and reviews. Our search results including the selection
process are presented in Fig. 3 according to PRISMA
guidelines.
Selection criteria
Our inclusion criteria were as follows:
a. Studies investigating humans only
b. Any age group
c. Clinical diagnoses of AN, BN, or BED according
to Diagnostic and Statistical Manual of Mental
Disorders versions IV or 5 and their revisions [38]
or International Classification of Diseases [39]
d. Investigation of any type of epigenetic mechanism:
methylation, histone modification, non-coding RNAs
e. Published after 01.01.2003 (date that the first article
on epigenetics of eating disorders appears in the
literature)
f. Study includes a control group or comparison group
g. Publications in any language
Data extraction




c. Sample including gender and age
d. Follow-up period
e. Diagnostic criteria
f. Participant screening and exclusion criteria
g. Number of cases (AN, BN, BED)
h. Number of controls
i. Matching of cases and controls
j. Outcome variables (Genome-wide methylation level,
candidate genes, number of CpG sites)
k. Covariates
l. Tissue
m. Correction for multiple comparison
n. Laboratory methods
o. Limitations
Quality of evidence assessment (GRADE criteria)
We used the GRADE criteria to assess the quality of evi-
dence of each outcome in our review against eight criteria,
including risk of bias, indirectness, inconsistency, impreci-
sion, and publication bias [40]. The quality is graded high,
moderate, low, or very low and reflects the degree of
confidence in the reviewed effects. We assessed the quality
of evidence for the three outcomes based on their study
design: global methylation level, all candidate genes toge-
ther, and EWAS associations.
Results
A total of 178 papers were identified by our search terms.
We excluded 67 studies because they did not cover
eating disorders, six did not investigate humans, 19 were
reviews, one was a book chapter, and three did not
examine epigenetic mechanisms. This resulted in 16
published studies and two conference abstracts on epige-
netics that met our predetermined inclusion criteria
(Fig. 3). One full-text article was a duplicate of a con-
ference abstract, resulting in 17 studies. To our knowledge
these represent all published studies and conference
abstracts investigating epigenetics in eating disorders that
were available at the close of our search in October,
2017. We contacted authors of conference abstracts for
additional information on their studies (Table 1).
Recent body of evidence
To date, 17 studies on the epigenetics of eating disorders
have been published of which four investigated global
DNA methylation levels, 13 investigated candidate genes,
and three used microarray-based technologies to profile
DNA methylation across the human genome. One study
design was longitudinal, but within this study one time
point was selected and analysed cross-sectionally [41].
All other studies were purely cross-sectional in design
and analysis. Studies primarily investigated young adult
females and focused exclusively on DNA methylation
and some also investigated expression levels, but did not
investigate other epigenetic mechanisms, such as histone
modifications or non-coding RNAs (Table 1). The studies
show extensive sample overlap as four studies are part
of the homocysteine and DNA methylation in eating
disorders (HEaD) study [42–45], two studies recruited
inpatients at the Universitätsmedizin Charité Berlin,
Germany [46, 47], and four studies recruited at the
Douglas Institute Eating Disorders Program in Montreal,















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Canada [48–51]. Most studies investigated surrogate tis-
sues with regard to their biological hypotheses, including
whole blood, lymphocytes, or buccal cells instead of
brain or metabolic tissue, and did not correct for hetero-
geneity of these tissues. Ten studies discussed the lim-
itations of using surrogate tissues in their articles, two
mentioned the issue, and four did not elaborate on this
limitation (Table 1).
Global DNA methylation levels
Four studies investigated global DNA methylation dif-
ferences in eating disorders. All studies primarily focused
on AN [45, 51–53], with one study also investigating BN
[45]. Two studies reported global hypomethylation in
individuals with AN [45, 53], one study reported global
hypermethylation in AN [51], and one reported no dif-
ference in global DNA methylation levels between AN
cases and controls [52]. Patients suffering from BN
showed no difference in their global DNA methylation
levels compared with controls [45]. Overall the quality
of evidence resulting from these studies was very low
with inconsistent findings of opposite effects (Supple-
mentary Table 1).
Candidate gene studies
Candidate gene studies are hypothesis-driven and investi-
gate DNA methylation in the vicinity of selected genes.
These candidate genes are selected based on prior knowl-
edge, for example, following differences in protein levels
measured in clinical studies assessing patients with AN
or BN. Overall, 13 studies have been published profiling
DNA methylation in candidate gene regions in the context
of eating disorders, twelve of which focus on AN (n = 9)
and BN (n = 6). These twelve studies investigated genes
relating to synaptic transmission [45], endoplasmatic reti-
culum stress response [45], growth hormone signaling [52],
fluid balance [42], the cannabinoid system [43], dopamine
transmission [44, 50, 54], stress response [46, 48], appetite
regulation [46, 49, 54], serotonin transmission [54], and
oxytocin [55]. One methylomic study of candidate genes in
BED has been reported [56, 57]. The study investigated
promoter methylation of SLC1A2, a gene involved in glu-
tamate clearance, in bipolar disorder. The authors found
decreased DNA methylation in bipolar disorder patients
who also suffered from BED, compared to those who were
only affected by bipolar disorder. However, their sample of
patients reporting binge-eating behavior seemed to com-
prise BN and BED cases, rendering the interpretation of the
results ambiguous [56, 57]. All candidate gene studies of
eating disorders are described in detail in Table 1. The


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































sample sizes never exceeding ~120 participants (Supple-
mentary Table 1).
Epigenome-wide association studies (EWAS)
Three EWAS investigated genome-wide DNA methyla-
tion profiles in AN using the Illumina Infinium®
HumanMethylation450 BeadChip. No genome-wide stu-
dies of DNA methylation have been published on other
eating disorders. Booij et al [51] reported 14 differentially
methylated CpG sites comparing 29 AN patients with 15
normal-weight controls. These 14 hypermethylated CpG
sites were annotated to 11 genes (PRDM16, HDAC4,
TNXB, FTSJD2, PXDNL, DLGAP2, FAM83A, NR1H3,
DDX10, ARHGAP1, PIWIL1) [51]. Kesselmeier et al. [30]
reported 51 differentially methylated CpG sites when
comparing 22 AN cases with 24 lean individuals and 81
CpG sites when comparing AN cases with 30 individuals
from a general population sample. They also showed that
54 of the 81 sites exhibited directionally consistent dif-
ferential DNA methylation differences in a comparison of
twins discordant for AN assessed by a binomial sign test
(Table 2). Although the authors report a replication of
hypermethylation previously reported at a CpG site
annotated to TNXB [30, 51], the significance level for this
replication was only suggestive. In this study, controls
recruited from the population were on average sig-
nificantly older than the AN patients potentially con-
founding the results as methylation patterns are age-
dependent [25, 30]. In a conference presentation, Ramoz
et al [41] conducted the only longitudinal investigation of
36 acutely ill AN patients of whom half remitted after one
year. However, the statistical analysis performed was
cross-sectional. No significant differences in DNA
methylation emerged between remitted AN patients and
those patients who were still ill after a follow-up period of
1 year. However, the study did not include a control group
[41]. Two of the three EWAS were followed up by
pathway analyses (Table 2) [41, 51].
Discussion
The current research on epigenetics in eating disorders is
limited and not yet sufficiently mature to draw sound con-
clusions with most evidence of the reviewed studies being of
very low quality. To date, epigenetic research in eating dis-
orders has, to our knowledge, focused exclusively on DNA
methylation, using three different approaches to investigate
disease-associated methylomic variation. First, early DNA
methylation studies measured global methylation levels in
eating disorder cases comparing them with methylation
levels in healthy controls. Second, DNA methylation at
selected candidate genes has been assessed. Third, genome-
wide approaches are applied in the investigation of epigenetic
alterations in EWAS. In general, studies were cross-sectional
and primarily focused on females. Most studies were con-
ducted on surrogate tissue and presented varying degrees of
acknowledgement and discussion of the limitations of using
surrogate tissues in epigenetic epidemiology.
Overall, global methylation study results were incon-
clusive and inconsistent and did not reveal a clear and
replicable global DNA methylation pattern in either AN or
BN. All four studies were small, with the largest study
profiling 32 AN cases and 24 BN cases, substantially lim-
iting the power to detect effects. More generally, global
levels of DNA methylation may not be of much relevance
to epigenetic epidemiology, as they fail to provide infor-
mation on region-specific DNA methylation, and lack the
specificity to associate the dysregulation of biological
pathways with the occurrence of a disease [58]. Even within
the framework of global DNA methylation studies, the
methods employed in these four studies limit the exam-
ination of DNA methylation to either promoter regions (for
Table 2 Epigenome-wide association study (EWAS) follow-on investigations
Author (Year) Multiple testing
correction
Variability filters Follow-up on hits Validation on
different platform
Function of identified sites
Booij (2015) Bonferroni and
False Discovery
Rate (FDR)
Probes needed to have a
standard deviation of at





No Histone acetylation and
RNA modification,





None Average beta value
across all samples







Ramoz (2017) n.a. n.a. Pathway analysis n.a. n.a.
n.a. not available, RNA ribonucleic acid, AN anorexia nervosa
the approaches based on methylation sensitive restriction
enzymes) or LINE1 elements [52], overlooking other parts
of the genome.
Across candidate gene studies, no clear differentially
methylated candidate genes for AN, for BN, or for BED
were robustly identified. Most candidate regions were
only profiled once, and results of repeatedly measured
genes involved in dopamine signaling did not replicate
across studies [44, 50, 54], showing no clear eating
disorder-associated methylomic variation across the
selected candidate genes. In addition to non-replication,
these studies were limited by small sample sizes render-
ing them imprecise: most of the study populations
included on average only 30 cases with two studies
including 64 cases [49, 50]. Furthermore subjects occa-
sionally comprised a mixture of acutely ill and recovered
patients [55] or a mixture of different eating disorders
[56, 57] introducing heterogeneity. This is particularly
concerning as dietary changes, weight changes, and
accompanied alterations of hormonal concentrations
during the recovery process can have a major effect on
epigenetic profiles in individuals with eating disorders.
Further possible confounders are discussed below. In
epigenetics, as in genetics, a general drawback of a can-
didate gene studies is their hypothesis-driven design.
Specific genes are selected for investigation based on
prior knowledge, narrowing the investigation to only a
very limited part of a large system and failing to attend to
the majority of other genomic regions.
In general, hypothesis-free approaches that explore the
whole genome are the gold standard in genetic research.
Genome-wide approaches are applied in the investigation
of common genetic variation (i.e., single nucleotide
polymorphisms, SNPs) in genome-wide association
studies (GWAS) as well as in the examination of epige-
netic alterations in EWAS. EWAS examining CpG sites
at a genome-wide level have identified multiple AN-
associated differentially methylated sites, replicating a
differentially methylated position at TNXB in one inde-
pendent study [51]. However, the hypermethylation at
this CpG site annotated to TNXB only reached suggestive
significance in the replication attempt [30], failing to
survive stringent correction for multiple comparisons. A
false positive finding, therefore, cannot be ruled out.
Statistically, EWAS share similarities with GWAS in
that site-specific associations with a phenotype across a
large number of genomic loci are conducted. These statis-
tical properties limited the findings in EWAS investigating
eating disorders: First, the reported samples never included
more than 29 cases of AN which is far too small to robustly
detect patterns of differential methylation at a genome-wide
scale, i.e., when conducting over 450,000 statistical tests
[59], leading to imprecise estimates of the effects. Second,
multiple testing correction was not always performed
stringently, e.g., when “suggestive” significant results were
reported or examined sites were filtered before or after
analysis based on methylation variability.
As such, many of the EWAS included above were
labeled as pilot studies by the authors and provide moti-
vation for further investigation, and are a springboard to
launch full-scale projects with larger sample sizes and
careful study design, data collection, and analysis. Future
studies will also require replication in independent sam-
ples and should adhere to stringent methodological cri-
teria, including multiple testing correction, no subjective




One of the primary goals of future epigenetic investiga-
tions of eating disorders should be to increase sample
sizes by international collaborations to improve the
power to detect effects, even when effect sizes are small.
Recent epigenetic studies of other psychiatric disorders
and environmental exposures have examined epigenetic
differences in samples comprising thousands of partici-
pants and notably, replicated successes have been docu-
mented for a number of exposures and diseases including
tobacco smoking [24], C-reactive protein levels in
serum blood [60], and Alzheimer’s disease [16, 17].
While several large consortium efforts have led to
advances in characterizing baseline human tissue epi-
genomes [10, 61, 62], this is rarely extended to the
realm of epigenetic epidemiology in complex diseases.
Unique challenges do exist in conducting large-scale
collaborative epigenetic studies. Combining raw data
(i.e., mega-analytic approaches) in epigenetics is pro-
blematic because technical variation in the data stemming
from different laboratories and procedures (i.e., batch
effects) has substantial impact on overall epigenomic
profiles and can be insufficiently controlled for by post-
hoc statistical or computational approaches [63, 64].
Nonetheless, approaches in which each site generates a
sufficiently large sample under nearly identical conditions
that can later be meta-analyzed are feasible [27]. Alter-
natively, consistent sampling at different study sites
including careful preanalytic sample collection and pro-
cessing followed by analysis in a central laboratory
could prevent many of the aforementioned technical
issues. However, this approach is only feasible if all
study sites meticulously follow the same protocol
regarding tissue sampling, sample handling, and pheno-
typing of participants to control for possible confounders
across study sites. This kind of pooling approach tends
to be complicated by challenges associated with sample
storage, transportation, and loss.
Statistical methods
As with any genome-wide investigation, the large number
of tests performed requires special considerations for
statistical analysis. Most importantly, it is essential to
correct for the number of tests performed. The latest
generation of DNA methylation arrays can simulta-
neously quantify epigenetic profiles at up to 850.000 CpG
sites. An EWAS then tests for associations between a
phenotype of interest and DNA methylation at each
of these sites. Each of the 850.000 tests has a small
probability of reporting a false positive association
(usually 5%). In order to keep the probability of making
any false positive discovery below this probability
threshold, the individual P value thresholds for each
test need to be adjusted, resulting in a genome- or array-
wide significance threshold. This correction for multiple
testing can be achieved by common methods such as
Bonferroni correction (dividing the P value threshold by
the number of tests conducted) or a false discovery rate
correction [65, 66].
Tissue specificity
Given the prominent role epigenetic mechanisms play
in cellular differentiation, genome-wide epigenetic pro-
files tend to differ substantially between different tissues
and cell-types, matching the differences in function (e.g.,
fat storage in adipose tissue vs. synaptic transmission
performed by neurons). Different cellular functions
require particular sets of proteins acting in concert (i.e.,
pathways) and epigenetic mechanisms control which
genes are active in which cell-type and tissue-context.
Interestingly, epigenetic profiles can distinguish func-
tionally different brain regions [67] and cell-types
[68, 69]. Is disease-associated epigenetic dysregulation
tissue-specific? For example, are epigenetic correlates
of psychiatric diseases restricted to the brain? In some
disorders, including AN, it is less straightforward to
pinpoint the affected tissue of interest. AN is character-
ized by both psychiatric and metabolic features [6].
Therefore, one would ideally investigate epigenetic pro-
files in both brain tissue and metabolic tissues (e.g.,
adipose tissue, pancreas, liver, stomach, and the intes-
tine). The investigation of brain in particular, however,
poses considerable challenges and is typically only
possible in postmortem samples, which introduces addi-
tional complications for epigenetic studies (e.g., time
of death, cause of death, etc.). Nonetheless, carefully
designed, ethical discussions of organ donations with
patients and families are worthy of consideration.
Surrogate tissues
Although investigation of epigenetic profiles in the
disease-affected tissue is the gold standard in epigenetic
studies, it is also valuable to examine epigenetics in sur-
rogate peripheral tissues, including whole blood, epithe-
lial cells, and saliva. First, while epigenetic profiles are
highly tissue-specific and profiles observed in peripheral
tissues are not generally representative of epigenetic
variation in brain, specific genomic regions manifest high
levels of epigenetic covariation [67, 70, 71]. For example,
an existing online platform allows for the profiling of
DNA methylation covariation between whole blood and
multiple brain regions (//epigenetics.essex.ac.uk/bloodbra
in/). Second, while results emerging from epigenetic
studies from peripheral samples might not necessarily
reflect the epigenetic changes in disorder-relevant tissues,
they can still be used as potential biomarkers, and are
collected more readily and less invasively than the
affected tissue itself. Importantly, when analyzing whole
blood epigenetic profiles, the blood cell-type composition
also needs to be assessed. Blood is a heterogeneous
organ comprised of distinct cell types, fulfilling specific
tasks, such as oxygen transport, immune function, and
nutrient distribution. Because blood composition in
patients suffering from eating disorders differs from
controls [30], it is imperative to control for these differ-
ences in cell-type composition. If unaccounted for, epi-
genetic differences identified in an association scan could
be related purely to differences in cellular composition
rather than epigenetic dysregulation directly linked
to disease etiology and progression. Where blood cell
counts are not available, validated estimators of subcell
proportions based on large reference panels can be used;
i.e., cell-type proportions can accurately be estimated
using microarray-based DNA methylation data. This
also applies to other cell-types, and estimators based on
DNA methylation array data have been previously
reported for whole brain, buccal swabs, and saliva sam-
ples. These estimators require array-wide DNA methyla-
tion profiles and are therefore not applicable in candidate
gene studies [72].
Genome-wide integrated epigenetic studies
Many of the studies reviewed here use targeted sequen-
cing approaches, which only allow the investigation of
DNA methylation in limited genomic regions and ignore
information from the rest of the genome. This may
increase the chances for false positive reports via a
publication bias of positive findings. Genome-wide tech-
nologies are less prone to this phenomenon and allow for
the verification of previously reported differentially
methylated sites. While only whole genome bisulfite
sequencing allows full coverage of the entire genome,
array-based approaches like Illumina’s EPIC array, allow
widespread coverage of CpG sites in most genomic
regions and can be a more cost-effective solution.
All epigenetic studies of eating disorders published
to date focused on DNA methylation only. A host of
other sources of regulatory variation including other
DNA modifications, histone modifications, and non-coding
RNAs should also be investigated. Furthermore, to better
interpret the role of epigenetic modifications in disease,
it is important to understand their interactions with the
genetic sequence itself. Integrated analyses incorporating
genotypic, epigenetic, transcriptomic, and detailed envir-
onmental data are beginning to emerge, elucidating the
role of disease-associated epigenetic dysregulation in
specific genetic and environmental contexts. Increasingly
detailed maps of genetic and (multi)epigenetic profiles in
health and disease will be essential to improve our under-
standing of the molecular biological pathways implicated
in complex disease.
Eating disorder-specific considerations
In addition to these general recommendations for improv-
ing epigenetic research in disease epidemiology, there
are also a number of important eating disorder-specific
complexities to be considered.
Eating disorder-specific confounders
Because epigenetic modifications are dynamic and can be
altered by environmental influences, epigenetic association
studies are subject to a wide range of confounders. Con-
founding in EWAS is comparable to classic observational
epidemiological studies and ideally these confounders
are addressed in the study design in such a way that they
can be controlled for in the statistical analyses. For example,
age, sex, diet, micronutrients, medication, dietary supple-
ments, hormones, smoking, and alcohol consumption can
interact with an individual’s epigenetic profile, obfuscating
EWAS analyses (Fig. 2).
A large body of evidence confirms that diet composi-
tion can have an effect on an individual’s epigenetic
profile [73–77]. Eating and compensatory behaviors can
include binge eating and purging behaviors, abuse of diet
medication, laxatives, and diuretics altering fluid balance.
It is important to record their typical use, as well as the
frequencies and recency of use and, ideally, obtaining
blood levels of diet medications when possible. Both
indicated and off-label prescribed antidepressants, antic-
onvulsants, and atypical antipsychotics are used to control
accompanying symptoms observed in patients suffering
from eating disorders [78]. Dosage and intake should be
included in the analysis, ideally, blood levels should be
measured, and statistical analyses corrected for. This
strategy should also be followed for supplements, such as
vitamins and micronutrients, and hormones as patients
with eating disorders often show hormonal alterations,
such as high cortisol and low sex hormones [79, 80].
These types of hormones are direct ligands to so-called
promoters, enhancers, and silencers and, therefore,
influence gene expression and protein levels directly.
Weight differences between cases and controls should be
accounted for; however, if substantial between group
differences exist between cases and controls, disease and
weight-associated epigenetic variation will remain con-
voluted. One option in addressing this issue is using a
matched weight control group, potentially in addition to
normal weight controls, in order to tease apart epigenetic
correlates of eating disorder versus altered weight phe-
notypes. However, this approach may be limited because
constitutionally thin individuals rarely have a BMI as low
as patients suffering from severe AN. Environmental
toxins, such as smoking and alcohol, can have a profound
impact on the epigenome. For example, prevalence dif-
ferences in smoking between cases and controls have been
shown to confound the association between DNA
methylation and schizophrenia [14].
As with every observational study design, the causal
attribution of epigenetic associations in eating disorders is
extremely difficult. The epigenetic dysregulation
could potentially have causally contributed to the disease or
have arisen as a consequence of the disease, its symptoms
or even treatments, such as medication; [81] or, in a third
scenario, there could be a third factor driving both the
disease and the epigenetic alteration, which have no direct
link between one another. One important approach to
addressing causality is to consider temporal factors [26, 27].
A variety of chronologically variable factors should be
taken into account, such as age of disorder onset, duration
of illness, onset of menstrual disturbances, and duration of
amenorrhea (in women). Longitudinal sampling and within-
subject comparisons can help differentiate between sequelae
of starvation or overeating and epigenetic factors that con-
tribute to the liability to develop an eating disorder.
In addition to this, methods using genetic variants as
instrumental variables can improve causal inference.
In epigenetic epidemiology, Mendelian randomization is of
particular importance, exploiting genetic influences
on DNA methylation (mQTLs) to understand whether
phenotypic associations of DNA methylation are indeed
causal [82].
Conclusion
Epigenetic research in eating disorders is still in its
infancy, but initial results from pilot studies encourage
further and larger-scale investigation. Much like progress
in genomics, international collaborations are required to
amass adequately powered sample sizes to draw credible
conclusions from epigenetic investigations. Even more
importantly, careful study design is of vital importance
in epigenetics and can aid in avoiding potential pitfalls.
Robust, replicable results from carefully designed studies
have the potential to uncover the molecular biological
processes involved in disease onset and progression,
they may help characterize gene regulatory effects of non-
coding genetic variation, and, hopefully, give indications
into disease-relevant biological pathways which could
be addressed by therapeutic interventions. Clearly a
considerable amount of functional work is required in
follow-up of epigenetic association studies to better
understand the gene regulatory, cellular, and organismal
outcomes of epigenetic variation and derive potential
translational implications and therapeutic avenues. Even
non-functional disease-associated epigenetic variation
from peripheral tissue sources could, however, have use-
ful implications as biomarkers for risk and prognosis
assessment and for use in early diagnosis.
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